share_log

WuXi AppTec Co., Ltd. (SHSE:603259) Institutional Owners May Be Pleased With Recent Gains After 9.0% Loss Over the Past Year

WuXi AppTec Co., Ltd. (SHSE:603259) Institutional Owners May Be Pleased With Recent Gains After 9.0% Loss Over the Past Year

無錫康德科普股份有限公司(SHE:603259)機構業主可能對過去一年 9.0% 虧損後的近期收益感到滿意
Simply Wall St ·  2023/01/22 19:35

A look at the shareholders of WuXi AppTec Co., Ltd. (SHSE:603259) can tell us which group is most powerful. We can see that institutions own the lion's share in the company with 41% ownership. Put another way, the group faces the maximum upside potential (or downside risk).

看看藥明康德股份有限公司(上交所股票代碼:603259)的股東,我們就知道哪個集團最有權勢。我們可以看到,機構擁有該公司最大的份額,擁有41%的股權。換句話説,該集團面臨着最大的上行潛力(或下行風險)。

Last week's CN¥19b market cap gain would probably be appreciated by institutional investors, especially after a year of 9.0% losses.

上週人民幣190億元的市值增長可能會受到機構投資者的讚賞,尤其是在經歷了9.0%的虧損之後。

Let's take a closer look to see what the different types of shareholders can tell us about WuXi AppTec.

讓我們仔細看看不同類型的股東能告訴我們關於藥明康德的什麼。

See our latest analysis for WuXi AppTec

參見我們對藥明康德的最新分析

ownership-breakdown
SHSE:603259 Ownership Breakdown January 23rd 2023
上海證交所:603259所有權明細2023年1月23日

What Does The Institutional Ownership Tell Us About WuXi AppTec?

關於藥明康德,機構所有制告訴了我們什麼?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

機構通常在向自己的投資者報告時,以基準來衡量自己,因此一旦一隻股票被納入主要指數,它們往往會對這隻股票變得更加熱情。我們預計,大多數公司都會有一些機構登記在冊,特別是在它們正在增長的情況下。

As you can see, institutional investors have a fair amount of stake in WuXi AppTec. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at WuXi AppTec's earnings history below. Of course, the future is what really matters.

如你所見,機構投資者對藥明康德持有相當多的股份。這意味着為這些機構工作的分析師已經看過了這隻股票,他們喜歡它。但就像其他人一樣,他們也可能錯了。如果多家機構同時改變對一隻股票的看法,你可能會看到股價迅速下跌。因此,下面藥明康德的收入歷史值得一看。當然,未來才是真正重要的。

earnings-and-revenue-growth
SHSE:603259 Earnings and Revenue Growth January 23rd 2023
上海證交所:603259收益和收入增長2023年1月23日

Hedge funds don't have many shares in WuXi AppTec. With a 7.2% stake, CEO Ge Li is the largest shareholder. For context, the second largest shareholder holds about 5.4% of the shares outstanding, followed by an ownership of 4.7% by the third-largest shareholder.

對衝基金對藥明康德的持股並不多。首席執行官葛Li持有該公司7.2%的股份,是其最大股東。作為參考,第二大股東持有約5.4%的流通股,第三大股東持有4.7%的股份。

A closer look at our ownership figures suggests that the top 22 shareholders have a combined ownership of 50% implying that no single shareholder has a majority.

仔細觀察我們的持股數據就會發現,前22名股東總共擁有50%的股份,這意味着沒有單一股東擁有多數股權。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

研究機構持股是衡量和篩選股票預期表現的好方法。通過研究分析師的情緒,也可以達到同樣的效果。有相當數量的分析師追蹤該股,因此瞭解他們對未來的總體看法可能是有用的。

Insider Ownership Of WuXi AppTec

藥明康德的內部人所有權

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

儘管對內部人的準確定義可能是主觀的,但幾乎每個人都認為董事會成員是內部人。公司管理層對董事會負責,董事會應代表股東的利益。值得注意的是,有時最高層管理人員本身也是董事會成員。

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

內部人持股是積極的,當它標誌着領導層像公司的真正所有者一樣思考時。然而,高內部人持股也可以給公司內部的一個小團體帶來巨大的權力。在某些情況下,這可能是負面的。

We can report that insiders do own shares in WuXi AppTec Co., Ltd.. The insiders have a meaningful stake worth CN¥21b. Most would say this shows a good alignment of interests between shareholders and the board. Still, it might be worth checking if those insiders have been selling.

我們可以報告,內部人士確實持有藥明康德股份有限公司的股份。內部人士持有價值210億元人民幣的可觀股份。大多數人會説,這表明股東和董事會之間的利益得到了很好的一致。不過,這些內部人士是否一直在拋售股票,或許值得一查。

General Public Ownership

一般公有制

The general public-- including retail investors -- own 32% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

包括散户投資者在內的普通公眾持有該公司32%的股份,因此不能輕易忽視。這種規模的所有權雖然可觀,但如果決策與其他大股東不同步,可能不足以改變公司政策。

Private Equity Ownership

私募股權所有權

Private equity firms hold a 5.4% stake in WuXi AppTec. This suggests they can be influential in key policy decisions. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

私募股權公司持有藥明康德5.4%的股份。這表明,他們可以在關鍵的政策決策中發揮影響力。有時我們會看到私募股權投資長期存在,但總的來説,它們的投資期限較短,而且--顧名思義--不會對上市公司進行太多投資。一段時間後,他們可能會考慮出售並將資本重新配置到其他地方。

Private Company Ownership

私營公司所有權

We can see that Private Companies own 15%, of the shares on issue. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

我們可以看到,私營公司擁有15%的已發行股份。或許有必要對此進行更深入的研究。如果關聯方,如內部人士,對這些私營公司中的一家有利害關係,則應在年報中披露。私營公司也可能對該公司擁有戰略利益。

Next Steps:

接下來的步驟:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For instance, we've identified 3 warning signs for WuXi AppTec (1 doesn't sit too well with us) that you should be aware of.

我發現看看到底是誰擁有一家公司是非常有趣的。但為了真正獲得洞察力,我們還需要考慮其他信息。例如,我們已經確定藥明康德的3個警示標誌(1對我們來説不太合適),這一點你應該知道。

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

如果你像我一樣,你可能會想一想這家公司是會增長還是會萎縮。幸運的是,您可以查看這份顯示分析師對其未來預測的免費報告。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的數字是使用過去12個月的數據計算的,指的是截至財務報表日期的最後一個月的12個月期間。這可能與全年的年度報告數字不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論